Nivedha Raveinthiranathan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nivedha Raveinthiranathan has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dirk van Niekerk
Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada
1 shared publication - Gina Ogilvie
Women's Health Research Institute Vancouver British Columbia Canada
1 shared publication - Jonathan Simkin
British Columbia Cancer Registry, Provincial Health Services Authority, Vancouver, Canada
1 shared publication - Laurie W. Smith
Women’s Health Research Institute, BC Women’s Hospital and Health Services, Vancouver, Canada. 1
1 shared publication - Marette Lee
Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada
1 shared publication - Robine Donken
School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
1 shared publication
Latest Publications
- Open Access
- 18 August 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (8) , 7692-7705
Age-Specific Trends of Invasive Cervical Cancer Incidence in British Columbia, Canada, 1971–2017
This study examined invasive cervical cancer (ICC) incidence trends in British Columbia (BC) by age and stage-at-diagnosis relative to World Health Organization ICC elimination targets (4 per 100,000 persons). Incident ICC cases (1971–2017) were obtained from the BC Cancer Registry. Annual age-standardized incidence rates (ASIRs) per 100,000 persons were generated using the direct method. ASIRs were examined among all ages 15+ years and eight age groups using Joinpoint Regression with the Canadian 2011 standard population. Standardized rate ratios (SRRs) compared stage II–IV (late) versus stage I (early) ASIRs by age (2010–2017). ICC ASIRs did not reach the elimination target. ASIRs declined from 18.88 to 7.08 per 100,000 persons (1971–2017). Stronger declines were observed among ages 45+ years, with the largest decline among ages 70–79 years (AAPC = −3.2%, 95% CI = −3.9% to −2.6%). Among ages 25–69 years, varying levels of attenuation in declining trends and stabilization were observed since the 1980s. SRRs indicated higher rates of late-stage ICC among ages 55+ years (SRR−55–69 years = 1.34, 95% CI = 1.08–1.71). Overall, ICC incidence declined in BC since 1971 but did not reach the elimination target. The pace of decline varied across age groups and increased with age. Continued efforts are needed to progress cervical cancer elimination among all age groups.
- 18 August 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (8) , 7692-7705
Open AccessAge-Specific Trends of Invasive Cervical Cancer Incidence in British Columbia, Canada, 1971–2017
This study examined invasive cervical cancer (ICC) incidence trends in British Columbia (BC) by age and stage-at-diagnosis relative to World Health Organization ICC elimination targets (4 per 100,000 persons). Incident ICC cases (1971–2017) were obtained from the BC Cancer Registry. Annual age-standardized incidence rates (ASIRs) per 100,000 persons were generated using the direct method. ASIRs were examined among all ages 15+ years and eight age groups using Joinpoint Regression with the Canadian 2011 standard population. Standardized rate ratios (SRRs) compared stage II–IV (late) versus stage I (early) ASIRs by age (2010–2017). ICC ASIRs did not reach the elimination target. ASIRs declined from 18.88 to 7.08 per 100,000 persons (1971–2017). Stronger declines were observed among ages 45+ years, with the largest decline among ages 70–79 years (AAPC = −3.2%, 95% CI = −3.9% to −2.6%). Among ages 25–69 years, varying levels of attenuation in declining trends and stabilization were observed since the 1980s. SRRs indicated higher rates of late-stage ICC among ages 55+ years (SRR−55–69 years = 1.34, 95% CI = 1.08–1.71). Overall, ICC incidence declined in BC since 1971 but did not reach the elimination target. The pace of decline varied across age groups and increased with age. Continued efforts are needed to progress cervical cancer elimination among all age groups.